By Application
Hot products 
-
Mouse Anti-AMIGO2 Recombinant Antibody (CBYY-C0756) (CBMAB-C2192-YY)
-
Mouse Anti-CD24 Recombinant Antibody (HIS50) (CBMAB-C10123-LY)
-
Rat Anti-CD63 Recombinant Antibody (7G4.2E8) (CBMAB-C8725-LY)
-
Mouse Anti-DES Monoclonal Antibody (440) (CBMAB-AP1857LY)
-
Mouse Anti-dsRNA Recombinant Antibody (2) (CBMAB-D1807-YC)
-
Mouse Anti-CDK7 Recombinant Antibody (CBYY-C1783) (CBMAB-C3221-YY)
-
Mouse Anti-CARD11 Recombinant Antibody (CBFYC-0811) (CBMAB-C0866-FY)
-
Rabbit Anti-BRCA2 Recombinant Antibody (D9S6V) (CBMAB-CP0017-LY)
-
Mouse Anti-CD24 Recombinant Antibody (2Q1282) (CBMAB-C1624-CN)
-
Mouse Anti-C4B Recombinant Antibody (CBYY-C2996) (CBMAB-C4439-YY)
-
Rat Anti-EPO Recombinant Antibody (16) (CBMAB-E1578-FY)
-
Mouse Anti-GSDMA Recombinant Antibody (CBLG1-2983) (CBMAB-G5128-LY)
-
Mouse Anti-2C TCR Recombinant Antibody (V2-1556) (CBMAB-0951-LY)
-
Mouse Anti-AGK Recombinant Antibody (V2-258056) (CBMAB-M0989-FY)
-
Mouse Anti-CD247 Recombinant Antibody (6B10.2) (CBMAB-C1583-YY)
-
Mouse Anti-APOE Recombinant Antibody (A1) (CBMAB-0078CQ)
-
Mouse Anti-ENO2 Recombinant Antibody (85F11) (CBMAB-0276CQ)
-
Mouse Anti-CD33 Recombinant Antibody (6C5/2) (CBMAB-C8126-LY)
-
Mouse Anti-ABL2 Recombinant Antibody (V2-179121) (CBMAB-A0364-YC)
-
Mouse Anti-CECR2 Recombinant Antibody (CBWJC-2465) (CBMAB-C3533WJ)
Cervical Cancer
Fig.1 Cervical cancer
Cervical cancer is a cancer originated from the cervix. Globally, cervical cancer is the fourth-most common cause of death from cancer among women and fourth-most common cause of cancer. At early stage, typically no symptoms are been found. However, later symptoms may include pelvic pain, vaginal bleeding, or pain during sexual intercourse. While bleeding after sex may not to be treated seriously, it may also reveal the presence of cervical cancer. Human papillomavirus (HPV) infection leads to about 90% of cases, followed by smoking. However, majority of people who have had HPV infections, do not develop cervical cancer. Cervical cancer typically develops from precancerous changes for 10 to 20 years. Around 90% of cervical cancer cases are diagnosed as squamous cell carcinomas, 10% are adenocarcinoma, and a small number are other types. Some novel prognostic markers, like TBLR1, MicroRNA-497, have been studied recently.
